Investors

Press Releases

Press Releases

Feb 01, 2023

Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23

Jan 10, 2023

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

Jan 04, 2023

Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary

Jan 03, 2023

Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

Investor Contact

Bruce Jacobs, CFA, MBA
Chief Financial Officer
investors@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+ 1 339.970.2843

Media Contact

Todd Cooper
Sr. Vice President, Corporate Affairs
media@kymeratx.com

Sign Up for Email Alerts